HAVCR2 and neoplasm: On the other hand, in the middle and late stages of tumour formation, TIM-3+ Tregs proliferate, thereby blocking the function of effector T cells.29 When TIM-3 was blocked with an anti-TIM-3 monoclonal antibody, the antitumor response of T cells mediated by IFN-γ was promoted.29